Standards, Options and Recommendations for tumor markers in colorectal cancer;Standards, Options et Recommandations: Marqueurs tumoraux sériques dans les cancers du côlon

Bulletin du Cancer

Volumn 88, Issue 12, 2001, Pages 1177-1206

  Eche, Nicole ^a   Pichon, Marie France ^a   Quillien, Véronique ^a   Gory Delabaere, Guillaume ^a   Riedinger, Jean Marc ^a   Basuyau, Jean Pierre ^a   Daver, Alain ^a   Buecher, Bruno ^a   Conroy, Thierry ^a   Dieu, Lise ^a   Bidart, Jean Michel ^a   Deneux, Laurent ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

CA 19 9; Carcinoembryonic antigen; Colorectal neoplasms; Guidelines; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CANCER; DIAGNOSTIC VALUE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MEDLINE; METHODOLOGY; PALLIATIVE THERAPY; PATIENT MONITORING; PRACTICE GUIDELINE; PROGNOSIS; REVIEW;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FRANCE; HUMANS; N-ACETYLNEURAMINIC ACID; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0035682948     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (245)

1. Carcinoembryonic antigen: Its role as a marker in the management of cancer. Summary of an NIH consensus statement
2. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial
3. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
4. Repeat hepatectomy for colorectal liver metastases
5. Standards, Options et Recommandations pour la prise en charge des patients atteints de cancer du côlon
6. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer
7. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma
8. A prospective study of current diagnostic procedures for assessment of hepatic metastases in colorectal cancers
9. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma
10. Radioimmunoguided surgery for recurrent colorectal cancer manifested by isolated CEA elevation
11. Is carcinoembryonic antigen useful in the follow-up management of patients with colorectal liver metastases?
12. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors
13. Surgical resection of pulmonary metastases from colorectal carcinoma: Five-year survival and main prognostic factors
14. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
15. Standards, Options et Recommandations: Marqueurs tumoraux sériques et cancer du sein
16. Redefined nomenclature for members of the carcinoembryonic antigen family
17. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer
18. Five-year survival versus initial concentrations and longitudinal serum CEA patterns in patients with colorectal carcinoma
19. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule
20. Routine compared with nonscheduled follow-up of patients with « curative » surgery for colorectal cancer
21. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum
22. A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma
23. Attitudes towards detection and management of hepatic metastases of colorectal origin: A second look
24. Follow-up of patients with colorectal cancer: A meta-analysis
25. Tumours markers. Calcitonin and carcinoembryonic anrigen in medullary carcinoma of the thyroid
26. CA19-9 as a marker for ovarian cancer: Alone and in comparison with CA125
27. Modelling of serial carcinoembryonic antigen changes in colorectal cancer
28. Is CEA analysis of value in screening for recurrences after surgery for colorectal carcinoma?
29. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer
30. Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer
31. Differences in serum tumor markers between colon and rectal cancer: Comparison of CA 242 and carcinoembryonic antigen
32. Tumor markers in chronic renal failure and hemodialysis patients
33. Modulation of differentiation and proliferation in human colon carcinoma cells by transforming growth factor beta 1 and beta 2
34. Induction of carcinoembryonic antigen secretion and modulation of protein secretion/expression and fibronectin/laminin expression in human colon carcinoma cells by transforming growth factor-beta
35. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer
36. Predominant expression of mRNA coding for nonspecific cross-reacting antigen in colorectal carcinomas
37. CEA for monitoring colon cancer
38. Colon cancer
39. « Oncocheck »: An international external quality assessment scheme for immunoassays of tumor markers
40. Standards, Options et Recommandations pour la surveillance après traitement d'un cancer du côlon
41. Proceedings: Carcinoembryonic antigen. Report of a screening study
42. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9
43. Comparing predictive decision rules in postoperative CEA monitoring
44. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology
45. Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis
46. Prognostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma
47. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer
48. Increased concentrations of the antigen CA 19-9 in serum of cystic fibrosis patients
49. Marqueurs tumoraux et dépistage des cancers: Les raisons d'un échec
50. Seric CA 19.9 levels in patients with non tumoral pathologies: Our experience in 892 cases
51. Use and limitations of serum total and lipid-bound sialic acid concentrations as markers for colorectal cancer
52. Quantitative qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3
53. Mérhodologie de développement des Standards, Options et Recommandations diagnostiques et thérapeutiques en cancérologie
54. Prognostic value of CA 19.9 levels in colorectal cancer
55. Use of CA 19-9 in the early detection of recurrences in colorectal cancer: Comparison with CEA
56. CEA as a prognostic factor in colorectal cancer
57. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer
58. Carcinoembryonic antigen
59. Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy
60. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer: A prospective study of 866 patients
61. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies
62. Monoclonal antibody CC3C195, which detects cancer-associated antigens in serum, binds to the human Lea blood group antigen and to its sialylated derivative
63. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis
64. Purification and analysis of an 80-kDa carcinoembryonic antigen-binding protein from Kupffet cells
65. Carcinoembryonic antigen induces cytokine expression in Kuppfet cells: Implications for hepatic metastasis from colorectal cancer
66. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells
67. Surgery for lung metastases from colorectal cancer: Analysis of prognostic factors
68. Demonstration of tumor-specific antigens in human colon carcinoma by immunological tolerance and absorption techniques
69. The use of preoperative plasma CEA levels for the stratification of patients after curative resection of colorectal cancers
70. Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer
71. Detection of recurrent cancer of the colon and rectum
72. Interférences dues aux anticorps anti-immunoglobulines, un poison pour tous les dosages immunologiques.I. Origine des anticorps anti-immunoglobulines et mécanismes des interférences
73. Interférences dues aux anticoprs anti-immunoglobulines, un poison pour rous les dosages immunologiques. II. Interférences, mises en évidence et suppression
74. Evidence for the elevation of serum carcinoembryonic antigen and tumor- associated glycoprotein-72 levels in patients administered interferons
75. Ectopic expression of carcinoembryonic antigen by a melanoma cell leads to changes in the transcription of two additional cell adhesion molecules
76. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma
77. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer
78. TAG-72 expression and its role in the biological evaluation of human colorectal cancer
79. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the seta of patients with malignant and nonmalignant diseases: Comparison with carcinoembryonic antigen
80. CA 242, a new tumour marker for pancreatic cancer: A comparison with CA 19-9, CA 50 and CEA
81. Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: A comparison with CA 19-9 and CEA
82. Carcinoembryonic antigen in metastatic colorectal cancer
83. Chemistry and immunology of CEA, CA 19-9 and CA-50
84. Antigenic sites in carcinoembryonic antigen
85. The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues
86. Carcinoembryonic antigen and intra-arterial chemotherapy response of liver metastases
87. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: A multivariate analysis of 572 patients
88. Metastatic potential of human colorectal carcinoma SW1222 cells transfected with cDNA encoding carcinoembryonic antigen
89. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies
90. Serological pancreatic tumor markers and the MUC1 apomucin
91. Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases: Predictive value and implications for adjuvant treatment based on multivariate analysis
92. Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma
93. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis
94. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer
95. A comparative analysis of the serum levels of NCC-ST-439 CEA and CA19-9 in patients with colorectal carcinoma
96. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences
97. Comparison of serological expression of different epitopes on the CA50- carrying antigen CanAg
98. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3
99. Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease
100. Transcription of carcinoembryonic antigen in normal colon and colon carcinoma. In situ hybridization study and implication for a new in vivo functional model
101. CEA expression of colorectal adenocarcinomas is correlated with their resistance against LAK-cell lysis
102. The carcinoembryonic antigen (CEA) modulates effector-target cell interaction by binding to activated lymphocytes
103. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer
104. Decreased sensitivity of carcinoembryonic antigen cDNA-transfected cells to adriamycin
105. A prospective analysis of laboratory tests and imaging studies to detect hepatic lesions
106. Carcino-embryonic antigen may function as a chemo-attractant in colorectal-carcinoma cell lines
107. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: Analysis using a receiver operating characteristic curve
108. Carcinoembryonic antigen: Usefulness as a postsurgical method in the detection of recurrence in Dukes stages B2 and C colorectal cancers
109. 1-fetaprotein in the management of testicular teratoma
110. Colorectal carcinoma antigens detected by hybridoma antibodies
111. Serum carcinoembryonic antigen concentration doubling time correlates with tumor biology and life expectancy in patients with recurrent gastrointestinal carcinoma
112. TPS for monitoring of response to chemotherapy in gastrointestinal (GI) cancer
113. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma
114. Poor prognosis associated with elevated serum CA 19-9 level in advanced colorectal carcinoma, independent of DNA ploidy or SPF
115. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases
116. Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases
117. Role of imaging in abdominopelvic follow-up after resection of colorectal cancer
118. Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model
119. Rôles des antigènes carcinoembryonnaires dans la cancérisation et la progression tumorale
120. An immunoradiometric assay (IRMA) for the CA-50 antigen
121. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer
122. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer
123. Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma
124. Clinical significance of carcinoembryonic antigen (CEA) in patients with adenocarcinoma in colon and rectum
125. Long-term follow-up of colorectal carcinoma patients by repeated CEA radioimmunoassay
126. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II
127. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin
128. Plasma kinetic of 5-fluorouracil: A high correlation with tumor-marker evolution and response to the treatment in metastatic colorectal cancer
129. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial
130. FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA level: Experience in 72 patients
131. CA-50 and CA-19.9 as tumour markers: Which is preferable?
132. The use of CEA as an early indicator for gastrointestinal tumor recurrence and second-look procedures
133. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma
134. Antigenic heterogeneity of carcinoembryonic antigen in the circulation defined by monoclonal antibodies against the carbohydrate moiety of carcinoembryonic antigen and closely related antigens
135. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer
136. Valeur diagnostique d'un test: Applications cliniques
137. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study
138. Serum markers for breast and colorectal cancers
139. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer
140. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer
141. Is prolactin secreted ectopically?
142. Within-subject variation of carcinoembryonic antigen in colorectal cancer - Application of reference of change values and individual reference ranges to patient follow-up
143. Survival of patients with colorectal carcinoma: Possible prognostic value of tissular carbohydrate antigen 19.9 determination
144. Notion de probabilité
145. Prognostic values of serum CA 19-9 and CEA for colorectal cancer
146. Lewis and secretor gene dosages affect CA19-9 and DUPAN-2 serum levels in normal individuals and colorectal cancer patients
147. Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas
148. Treatment of metastatic cancer to the liver
149. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9
150. Serum carcinoembryonic antigen (CEA) correlates with the survival time during 5-FU hepatic arterial infusion chemotherapy for unresectable colorectal hepatic metastases
151. Dysregulation of carcinoembryonic antigen group members CGM2, CD66a (biliary glycoprotein), and nonspecific cross-reacting antigen in colorectal carcinomas. Comparative analysis by northern blot and in situ hybridization
152. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients
153. Carcinoembryonic antigen and recurrent colorectal cancer
154. CEA to detect recurrence of colon cancer
155. Realism or nihilism in bowel cancer follow-up?
156. Serial levels of CA 19-9 and CEA in colonic cancer
157. Incidence and patterns of recurrence following curative resection for colorectal carcinoma
158. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells
159. Detection of hepatic metastases in colorectal cancer: A prospective study of laboratory and imaging methods
160. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up
161. Preoperative carcinoembryonic antigen and prognosis in patients with colorectal cancer
162. Comparative study between alkaline phospharase and gamma-glutamyltranspeptidase in the diagnosis of hepatic metastases
163. Follow-up of patients operated on for colorectal carcinoma
164. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases
165. Plasma sialic acid as a marker of the effect of the treatment on metastatic colorectal cancer
166. Plasma prolactin in patients with colorectal cancer. Value in follow-up and as a prognosticator
167. Comparison between serum levels of carcinoembryonic antigen, sialic acid and phosphohexose isomerase in lung cancer
168. Technerium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels
169. 1959-1999: From serum markers to 18-FDG in oncology. The experience of the Rene-Huguenin Center
170. An evaluation of postoperative follow-up tests in colon cancer patients treated for cure
171. CA-50 as a tumour marker for monitoring colorectal cancer: Antigen rises in patients postoperatively precede clinical manifestations of recurrence
172. Role of follow-up in management of local recurrences of colorectal cancer: A prospective, randomized study
173. Elevated serum CA19-9 levels in poorly controlled diabetic patients: Relationship with Lewis blood group
174. Radioimmunoassisted follow-up and surgery vs traditional examinations and surgery after radical excision of colorectal cancer
175. Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
176. Outcome of follow-up programs in patients previously resected for colorectal cancer
177. Carcinoembryonic antigen, CA 19-9, and CA 125 in normal and carcinomatous human colorectal tissue
178. Assessment of serial carcinoembryonic antigen: Determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy
179. Disappearance curves of tumor markers after radical surgery
180. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma
181. Transient carcinoembryonic antigen (CEA) elevations following resection of colorectal cancer: A limitation in the use of serial CEA levels as an indicator for second-look surgery
182. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank
183. Role of carcinoembryonic antigen and liver function tests in the detection of recurrent colorectal carcinoma
184. Radical differences in functions of closely related members of the human carcinoembryonic antigen gene family
185. Follow-up of colorectal cancer: A meta-analysis
186. The 95-kilodalton membrane glycoprotein overexpressed in novel multidrugresistant breast cancer cells is NCA, the nonspecific cross- reacting antigen of carcinoembryonic antigen
187. CEA serum levels in non-neoplastic disease
188. A new approach for clinical biological assay comparison and standardization: Application of principal component analysis to a multicenter study of twenty-one carcinoembryonic antigen immunoassay kits
189. The value of CA 19-9 in gastric and colorectal carcinoma
190. Resection of colorectal liver metastases
191. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging
192. Cancer markers
193. Colorectal cancer. Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern
194. Carcinoembryonic antigen in serum of patients with colorectal polyps: Correlation with histology and smoking status
195. The effect of non-insulin-dependent diabetes on serum concentrations of tumor-associated carbohydrate antigens of CA19-9, CA-50, and sialyl SSEA-1 in association with the Lewis blood phenotype
196. Immunohistochemical expression of carbohydrate antigen 19-9 in colorectal carcinoma
197. Can preoperative and postoperative CEA predict survival after colon cancer resection?
198. Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer: A useful outcome predictor
199. Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer
200. Prognostic value of preoperative serum CEA level compared to clinical staging. I. Colorectal carcinoma
201. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies
202. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer
203. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?
204. CEA monitoring among patients in multi-institutional adjuvant G.I. therapy protocols
205. Carcinoembryonic antigen in an unselected elderly population: A four year follow up
206. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results
207. Value of serum levels of carcinoembryonic antigen, CEA, and gastrointestinal cancer antigen, GICA or CA 19-9, for preoperative staging and postoperative monitoring of patients with colorectal carcinoma
208. Predictive value of plasma CEA levels: Preoperative prognosis and postoperative monitoring of patients with colorectal carcinoma
209. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium
210. Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy
211. Screening for liver metastases from colorectal cancer with carcinoembryonic antigen and alkaline phosphatase
212. Plasma CEA in the post-surgical monitoring of colorectal carcinoma
213. Improved procedure for determination of serum lipid-associated sialic acid: Application for early diagnosis of colorectal cancer
214. The effect of transfection of the CEA gene on the metastatic behavior of the human colorectal cancer cell line MIP-101
215. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
216. Down-regulation of carcinoembryonic antigen family member 2 expression is an early event in colorectal tumorigenesis
217. Liver metastases with 10 human colon carcinoma cell lines in nude mice and association with carcinoembryonic antigen production
218. Evaluation of serum carcinoembryonic antigen monitoring in the follow-up of colorectal cancer patients with metastatic lymph nodes and a normal preoperative serum level
219. Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells
220. Comparison of doubling times of serum carcinoembryonic antigen produced by various metastatic lesions in recurrent gastric and colorectal carcinomas
221. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer
222. Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma
223. Serum sialic acid and carcinoembryonic levels in the detection and monitoring of colorectal cancer
224. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma
225. In vitro upregulation of carcinoembryonic antigen expression by combinations of cytokines
226. Calculation of half-life of carcinoembryonic antigen after lung tumour resection: A case report
227. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population
228. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon
229. Prospective monitoring trial for carcinoma of colon and rectum after surgical resection
230. The significance of CA19-9 tumor antigen in the serum of patients with carcinomas
231. Value of carcinoembryonic antigen in the management of colorectal cancer
232. Resection of liver metastases from colorectal cancer: Are there any truly significant clinical prognosticators?
233. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer
234. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B- 2, beta HCG immunohistochemistry in advanced colorectal cancer
235. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma
236. The miniscule benefit of serial carcinoembryonic antigen monitoring after effective curative treatment for primary colorectal cancer
237. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer: Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials
238. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies
239. Analysis of the early postoperative serum carcinoembryonic antigen time- course as a prognostic tool for bronchogenic carcinoma
240. Disappearance curves for tumor markers after resection of intrathoracic malignancies
241. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients